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Abstract
It has been shown that [18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) provides robust and
reproducible data for early metabolic response assessment in various malignancies. This led to the initiation of several
prospective multicenter trials in malignant lymphoma and adenocarcinoma of the esophagogastric junction, in order
to investigate whether the use of PET-guided treatment individualization results in a survival benefit. In Hodgkin
lymphoma and aggressive non-Hodgkin lymphoma, several trials are ongoing. Some studies aim to investigate the use
of PET in early identification of metabolic non-responders in order to intensify treatment to improve survival. Other
studies aim at reducing toxicity without adversely affecting cure rates by safely de-escalating therapy in metabolic
responders. In solid tumors the first PET response-adjusted treatment trials have been realized in adenocarcinoma of
the esophagogastric junction. These trials showed that patients with an early metabolic response to neoadjuvant
chemotherapy benefit from this treatment, whereas metabolic non-responders should switch early to surgery, thus
reducing the risk of tumor progression during chemotherapy and the risk of toxic death. The trials provide a model for
designing response-guided treatment algorithms in other malignancies. PET-guided treatment algorithms are the
promise of the near future; the choice of therapy, its intensity, and its duration will become better adjusted to the
biology of the individual patient. Todays major challenge is to investigate the impact on patient outcome of perso-
nalized response-adapted treatment concepts.
Keywords: [18F]Fluorodeoxyglucose; positron emission tomography; metabolic response-adjusted therapy; risk-adapted treatment;
PET-guided treatment; randomized controlled trials; malignant lymphoma; gastroesophageal cancer; breast cancer.
Introduction
For several years, fluorodeoxyglucose (FDG)-positron
emission tomography (PET) has become part of the
standard of care in staging and restaging of a variety
of malignant diseases, focusing on the detection of
malignant lesions at early stages and early detection
of recurrence and metastatic spread. FDG-PET has
been shown to be successful in distinguishing fibrosis
and scar tissue from viable tumor in residual masses
after therapy, in localization of recurrence in patients
with an unexplained increase in serum tumor markers
and as a tool for selecting patients eligible for surgical
treatment of metastatic disease. FDG-PET has had a
positive impact on overall staging and patient manage-
ment in various malignancies. Furthermore, in the past
decade a large number of studies have provided con-
siderable evidence that assessment of tumor glucose
utilization by FDG-PET provides an early readout for
the effectiveness of therapy, that it correlates with the
degree of histologic tumor regression and allows pre-
diction of patient survival. These studies have been
performed with several tumor types and during differ-
ent treatment modalities, such as chemotherapy, che-
moradiation, hormone and targeted therapy. This
success qualifies FDG-PET for its most exciting appli-
cation in randomized trials; comparing PET-controlled
strategies with standard patient management[1]. This
review discusses clinical trials and the work that has
been performed in early metabolic response-adapted
treatment of malignant lymphoma, gastroesophageal
cancer and breast cancer.
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FDG-PET-based risk-adapted studies
on malignant lymphoma
It has been recognized that interim FDG-PET provides
strong prognostic information in Hodgkin lymphoma and
aggressive B-cell non-Hodgkin lymphoma. The widely
cited study by Gallamini et al.[2] showed that the 2-year
progression-free survival was 95% in patients with a neg-
ative PET after 2 cycles of ABVD (doxorubicin, bleomy-
cin, vinblastine, dacarbazine), but only 13% in patients
with a positive interim PET (i.e. residual lesions with
FDG uptake clearly above normal mediastinal uptake).
In multivariate analysis, interim PET overshadowed the
prognostic value of the International Prognostic Scoring
(IPS) and emerged as the single most important tool for
planning of risk-adapted treatment in advanced Hodgkin
lymphoma[2]. This is not surprising, since the IPS com-
prises population-based, rather static, pre-treatment para-
meters in comparison with the dynamic metabolic
information of FDG-PET, which provides individualized
information about prognosis and quality of response to a
certain therapy. The definition of a negative or positive
interim PET was published in 2009 in a consensus report
known as the Deauville criteria[3]. These criteria are spe-
cifically designed for interim PET, in contrast to the
International Harmonization Project (IHP) end-of treat-
ment response evaluation criteria[4]. The advantages of
these former criteria include simplicity, high reproduci-
bility and preservation of the data on the degree of
response. This scoring system permits adaptation of the
thresholds of the binary scale (positive or negative)
according to the research question, i.e. a high positive
predictive value is desired when escalation of therapy is
intended, and a high negative predictive value is impor-
tant in case of de-escalation of treatment[5]. Attempts
have been made to improve the results by semi-quantita-
tive analysis of FDG uptake. However, current data sug-
gest that this does not have additional value in Hodgkin
lymphoma[68], but might be beneficial in the assessment
of response of non-Hodgkin lymphoma[9,10]. The success-
ful application of FDG-PET for early response assess-
ment in malignant lymphoma has opened up a unique
opportunity to use interim FDG-PET for stratification of
patients in risk-adapted treatment regimens. Survival out-
comes did not simply depend on PET response but also
on the promptness with which that occurred[11]. The
highly significant results of all these studies[2.68,1225]
provided a reliable basis for several (ongoing) clinical
trials in patients with Hodgkin lymphoma and aggressive
non-Hodgkin lymphoma, which investigate the value of
treatment adaptation based on early response monitoring
using interim FDG-PET (Tables 13). Indolent non-
Hodgkin lymphomas are less suitable for this kind of
trial because, in general, they are less FDG avid at base-
line. In addition, they generally show a long natural his-
tory and a high incidence of recurrence, which decreases
the clinical impact of a potential risk-adapted or
response-adapted approach. The following sections dis-
cuss the (ongoing) clinical trials on Hodgkin and non-
Hodgkin lymphoma, investigating the performance of
metabolic response-adjusted treatment.
Limited-stage Hodgkin lymphoma
Patients with limited-stage Hodgkin lymphoma are tradi-
tionally treated with combined chemo- and radiotherapy,
which now results in a 10-year overall survival of
8497%[26,27]. In early-stage Hodgkin lymphoma, in con-
sequence, treatment-related illnesses, such as acute leuke-
mia, second malignancies and cardiovascular diseases,
account for more deaths than Hodgkin lymphoma
itself[28]. Since Hodgkin lymphoma is typically a disease
of younger individuals, late treatment toxicities are a
major concern. Therefore, studies are now aiming at put-
ting the central slogan reduce if possible, intensify if
needed into practice[29]. Clinical trials have focused
on decreasing toxicities of overly intensive treatment
Table 1 Main risk-adapted trials using interim FDG-PET in limited disease Hodgkin lymphoma
Reference Study Group PET timing Treatment
[35] RAPID, NCT00943423 UK NCRI Post ABVD 3 PET()!randomize between RT or no further therapy;
PET(þ)!complete ABVD 1 þ RT
[36] HD16, NCT00736320 GHSG Post ABVD 2 Standard arm, RT regardless of PET
Experimental arm, PET()!no further therapy; PET(þ)!RT
[37] H10, NCT00433433 EORTC, Post ABVD 2 Standard arm, complete ABVD þ RT regardless of PET
GELA, IIL Experimental arm, PET()!complete ABVD;
PET(þ)!BEACOPPesc then RT
[39] 50604, NCT01132807 CALBG Post ABVD 2 PET()!complete ABVD 2; PET(þ)!BEACOPPesc 6
[38] 50801, NCT01118026 CALBG Post ABVD 2 PET()!complete ABVD 4; PET(þ)!BEACOPPesc 4 þ RT
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procar-
bazine, prednisone; CALBG, Cancer and Leukemia Group B; EORTC, European Organisation for Research and Treatment of Cancer; esc,
escalated; GELA, Groupe d Etude des Lymphomes de lAdulte; GHSG, German Hodgkin Study Group; IIL, Intergruppo Italiano Linfomi; RT,
radiotherapy; UK NCRI, United Kingdom National Cancer Research Institute.
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(without compromising disease control) in good-risk
patients, and on identifying poor-risk patients who
could benefit from treatment intensification (Table 1).
These efforts include the reduction of radiotherapy
dose and in the application of involved-field[30] and
involved-node[31] instead of extended-field radiotherapy.
In patients with non-bulky disease, chemotherapy alone
has emerged as a viable alternative to combined modality
treatment[32,33], although the risk of relapse is probably
higher compared with combined modality treatment[32].
Therefore, it is important to identify upfront those
patients who will be affected by the omission of radio-
therapy. It has been shown that the subset of patients
with a rapid response to chemotherapy, already after 2
cycles of ABVD, have a significantly better 5-year pro-
gression-free survival than those without an early
response (95% versus 81%, P¼ 0.007)[32]. Since PET
has been shown to be helpful in identifying this subset
of patients[2,6,7,20,21,2325,34], the impact of PET-based
approaches is now being evaluated. Four clinical trials
are investigating the performance of an interim
FDG-PET-based approach, omitting radiotherapy in
case of a negative PET after 23 cycles ABVD[3538].
If radiotherapy is omitted, however, there is a risk of
undertreatment if an adequate number of chemotherapy
cycles is not delivered, because a negative PET scan does
not reflect the complete absence of any viable malignant
cells[11]. To pursue a favorable outcome, additional or
unabbreviated chemotherapy is given to this PET-nega-
tive population in several trials in which radiotherapy is
withheld[3739]. In the HD16 trial[36] and the RAPID
trial[35], however, further treatment is stopped in the
experimental arm after a negative interim PET, given
that these trials are restricted to patients with early favor-
able disease. It must be emphasized that the PET-positive
population often faces the problem of the coexistence of
chemo- and radiotherapy resistance. It has been shown
that tumors with a suboptimal response to chemotherapy,
commonly show progression or relapse within the radia-
tion field[40]. In addition, radiotherapy should not neces-
sarily be considered the appropriate next step in the case
of a positive interim PET, because it may increase the
Table 2 Main risk-adapted trials using interim FDG-PET in advanced-stage Hodgkin lymphoma
Reference Study Group PET timing Treatment
[29] NCT00305149 ISRA Post BEACOPP(esc) 2 67Ga/PET(-)!BEACOPP 4
67Ga/PET(þ)!BEACOPPesc 4
[45] HD15, ISRCTN32443041 GHSG Post BEACOPPesc/14
68 þ RD 2.5 cm
PET()!follow-up,
PET(þ)!RT
[50] HD18, NCT00515554 GHSG Post BEACOPPesc 2 PET()!randomize between 2 and 6 more cycles
BEACOPPesc;
PET(þ)!randomize between BEACOPPesc þ or 
rituximab
Post-chemotherapy PET(þ) RD 2.5 cm!RT
[46] HD0607, NCT00795613 GITIL Post ABVD 2 PET()!complete ABVD; if still PET() randomize
between þ or  RT
PET(þ)!randomize between BEACOPPesc þ or 
rituximab
Post BEACOPPesc 4  rituximab
PET()!BEACOPP  rituximab
[47] RATHL, NCT00678327 UK NCRI Post ABVD 2 PET1()!randomize between ABVD 4 or AVD 4
PET1(þ)!BEACOPP-14 4 or BEACOPPesc
3!PET2;
PET2(þ)!RT or salvage
PET2()!PET(þ)!BEACOPP-14 2 or
BEACOPPesc 1
[51] HD0801, NCT00784537 IIL Post ABVD 2 PET()!complete ABVD; if still PET() randomize
between þ or  RT
PET(þ)!high dose therapy with autologous BMT
[48] S0816, NCT00822120 SWOG intergroup Post ABVD 2 PET()!further ABVD 2
PET(þ)!BEACOPPesc; standard BEACOPP if
human immunodeficiency virus positive
[77] CIA-HL-1, NCT01304849 Cancer Institute
(WIA), India
Post ABVD 2 PET()!further ABVD 2
PET(þ)!BEACOPPesc
[55] NCT00255723 Memorial Sloan-
Kettering Cancer
Center, New York
Post (ICE/ICEa) 2 PET()!HDT/ASCT
PET(þ)!GVD!no PD!HDT/ASCT
(a)ICE, (augmented) ifosfamide, carboplatin, etoposide; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etopo-
side, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone; esc, escalated; BMT, blood or marrow transplantation; GHSG,
German Hodgkin Study Group; GITIL, Gruppo Italiano Terapie Innovative Nei Linfomi; GVD, gemcitabine, vinorelbine, and liposomal doxor-
ubicin; HDT/ASCT, high-dose chemoradiation followed by autologous stem cell transplantation; IIL, Intergruppo Italiano Linfomi; ISRA, Israel
Rambam Health Care Campus; PD, progressive disease; RATHL, response-adapted therapy in Hodgkin lymphoma; RD, residual disease;
RT, radiotherapy; SWOG, Southwest Oncology Group; UK NCRI, United Kingdom National Cancer Research Institute.
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risk of toxicity from subsequent therapies, such as bone
marrow transplantation. So, although apparent progress
is being made, questions for optimal patient management
still remain and should be the focus of further research.
Advanced-stage Hodgkin lymphoma
In advanced Hodgkin lymphoma, the same questions as
in limited-stage Hodgkin lymphoma may arise: Does
outcome improve in interim PET-positive patients after
treatment intensification, and can toxicity be minimized
in PET-negative patients while retaining the high
efficacy? One standard of care, outside the setting of a
clinical trial, in patients with advanced Hodgkin lym-
phoma is 6 cycles of ABVD. Eight cycles of escalated
BEACOPP (bleomycin, etoposide, doxorubicin, cyclo-
phosphamide, vincristine, procarbazine, prednisone) is
superior to standard BEACOPP, COPP-ABVD (cyclo-
phosphamide, vincristine, procarbazine, prednisone and
ABVD) or ABVD in terms of disease control[4143], pro-
gression-free and overall survival[42,44]. It is, however,
more toxic and results in an increased risk of acute hema-
tologic toxicity, secondary myelodysplasia, acute leuke-
mia and infertility. This hindered its widespread
acceptance as standard therapy. Recent results from the
HD15 trial show superiority of both safety and efficacy of
6 cycles of BEACOPPesc over 8 cycles of BEACOPPesc.
In this trial, 2182 patients were randomly assigned to
receive either 8BEACOPPesc, 6BEACOPPesc, or
8BEACOPP14 (BEACOPP in baseline doses at 14-
day intervals). After a median follow-up of 48 months,
there were 53 deaths (7.5%) in the 8 BEACOPPesc
group, 33 (4.6%) in the 6 BEACOPPesc group and 37
(5.2%) in the 8 BEACOPP14 group. The higher number
of deaths in the 8 BEACOPPesc group mainly resulted
from acute toxicity of chemotherapy (15 vs 6 vs 6) and
second neoplasms (13 vs 5 vs 8). There were 72 second
cancers including 29 secondary acute myeloid leukemias
and myelodysplastic syndromes, 19 (2.7%) after 8
BEACOPPesc, 2 (0.3%) after 6 BEACOPPesc and 8
(1.1%) after 8 BEACOPPesc14. Freedom from treatment
failure at 5 years was 84.4% in the 8 BEACOPPesc
group, 89.3% in the 6 BEACOPPesc group, and 85.4%
in the 8 BEACOPPesc14 group, respectively. Overall sur-
vival at 5 years was 91.9%, 95.3%, and 94.5%, and was
also significantly better with 6 BEACOPPesc compared
with 8 BEACOPPesc[45]. However, this more effective
but more toxic treatment should be reserved for the
high-risk patient category. In several trials[4649], it is
being investigated whether patients with a positive
interim PET benefit from an approach including esca-
lated BEACOPP (Table 2). The first PET-driven clinical
trial in malignant lymphoma, published by Dann
et al.[29], showed that FDG-PET is a useful tool for
adjustment of chemotherapy on an individual basis
(Fig. 1). By using an FDG-PET-based risk-adapted
BEACOPP regimen they showed that the cumulative
dose of chemotherapy can be reduced for standard and
high-risk Hodgkin lymphoma with no detrimental effects
on outcome. One hundred and eight patients with newly
diagnosed Hodgkin lymphoma and adverse prognostic
factors were assigned to therapy according to defined
risk stratification based on the IPS. Patients with IPS
3 received 2 cycles of escalated BEACOPP. All
others received 2 cycles of standard BEACOPP.
Subsequent therapy was based on the results of early
interim 67Ga-scintigraphy or FDG-PET/computed tomo-
graphy (CT). In the case of a positive interim scan, 4
Table 3 Main risk-adapted trials using interim FDG-PET in non-Hodgkin lymphoma
Reference Study Group PET timing Treatment
[62] NCT01285765 GELA Post R-CHOP21 2
and 4
Standard arm, R-CHOP21 6
Experimental arm, PET2(/þ)!R-CHOP21 4;
PET4(þ) þ biopsy(þ)!intensive chemotherapy
PET CHOP Alberta Cancer Board Post R-CHOP 2 PET(þ)!salvage with high-dose chemotherapy þ ASCT
LNH20073B GELA Post R-CHOP 2 PET(þ)!salvage with high-dose chemotherapy þ ASCT
[78] NCT00324467 British Columbia
Cancer Agency
Post R-CHOP 4 PET()!R-CHOP 2
PET(þ)!R-ICE 4
[59] - Johns Hopkins Post (R)-CHOP 23 PET(þ)!salvage with high-dose chemotherapy þ ASCT
[79] PETAL,
NCT00554164
University Hospital, Essen Post (R)-CHOP 2 PET()!R-CHOP 4
PET(þ)!(R)-CHOP 6 or Burkitt regimen (B-ALL
protocol)
[63] NCT00712582 Memorial Sloan-Kettering
Cancer Center
Post RR-CHOP-14 3,
CHOP 1
PET()/PET(þ)þbiopsy()þKi67580%!ICE 3
PET()/PET(þ)þbiopsy() þ Ki6780%!augmented
R-ICE 2
Biopsy(þ)!opt for allogenic SCT
[64] Memorial Sloan-Kettering
Cancer Center
Post R-CHOP 4 PET()!ICE 3
PET(þ)/biopsy()!ICE 3
PET(þ)/biopsy(þ)!ICEþASCT
ASCT, autologous stem cell transplantation; GELA, Groupe d Etude des Lymphomes de lAdulte; PETAL, Positron Emission Tomography guided
therapy of Aggressive non-Hodgkin Lymphomas; R-CHOP, cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), predniso-
neþ rituximab; R-CHOP21, cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), prednisoneþ rituximab, G-CSF; R-ICE, ifosfamide,
carboplatin, etoposideþ rituximab.
24 Focus On 1: Emerging Paradigms in PET
HD
stage I-II, ≥1 
unfavourable 
features
stage III-IV
Non-high Risk
Low-risk, early 
unfavourable
Standard-risk, 
IPS≤2
High Risk
IPS≥3
2 cycles of 
standard 
BEACOPP
2 cycles of 
escalated 
BEACOPP
Interim Functional 
Imaging
67Ga-scintigraphy 
or 18F-FDG-PET/
CT
Baseline Functional Imaging 
(67Ga-scintigraphy or 18F-
FDG-PET/CT)
4 additional 
cycles of standard 
BEACOPP
4 additional 
cycles of 
escalated 
BEACOPP
Negative* Positive**
Functional 
Imaging
67Ga-scintigraphy 
or 18F-FDG-PET/
CT
No Radiation 
Therapy
Radiation Therapy
Negative* 
and no bulky 
mediastinum
Positive** or 
bulky 
mediastinum
Follow-up imaging every 6months for 2 years and 
once during 3rd year.
112 patients enrolled
- 4 patients non-evaluable
108 patients evaluable:
- 105 patients CR
- 9 disease relapse
- 3 patients PRD
Figure 1 Study scheme as used by Dann et al.[29]. BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine, prednisone; CR, complete remission; HD, Hodgkin disease; IPS, Hasenclever international
prognostic score; PRD, primary resistant disease (persistence of disease or occurrence of new lesions);
unfavorable features, B symptoms, bulky disease, 4 or more sites of disease, age 50years, erythrocyte sedimentation
rate 50 mm in first hour, lymphocyte-depleted histology or E site.*Negative, no foci of increased uptake unrelated to
physiologic or benign tracer uptake; **positive, any focus of increased uptake unrelated to physiologic or benign tracer
uptake.
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cycles of escalated BEACOPP were administered,
whereas 4 cycles of standard BEACOPP were given to
patients with a negative scan. The complete remission
rate, the 5-year event-free survival and 5-year overall sur-
vival rates were 97%, 85% and 90%, respectively. Relapse
or progression occurred in 27% of patients with interim
positive PET/CT versus 2.3% of negative scans
(P50.02). Although this approach has not been studied
in a randomized fashion, the results demonstrate that
only a minority of patients require upfront intensified
therapy. The HD18 trial[50] and the HD0607 trial[46]
also investigate the effectiveness of the addition of ritux-
imab, a drug that is effective on Reed Sternberg cells
despite the absence of CD20, to escalated BEACOPP.
In the interim PET-negative populations (Table 2) the
main questions are whether the number of chemotherapy
cycles can be reduced[50] and the pulmonary toxic agent
bleomycin[47] or consolidative radiotherapy[46,51] can be
omitted. Because of its cumulative late toxicities and
questionable impact on overall survival, up to now the
role of radiotherapy remains undefined in advanced-stage
Hodgkin lymphoma as well as in non-Hodgkin lym-
phoma[52]. Therefore, the HD15 trial[45] and the HD18
trial[50] omit radiotherapy in all patients with a negative
PET scan after BEACOPP. The HD15 trial[45] showed a
negative PET in 74% and a positive PET in 25% of
patients after 68 cycles of BEACOPP chemotherapy.
PET was performed in 728 patients with residual disease
42.5 cm, of whom 701 had at least 12 months of follow-
up. In the PET-negative group, 22 patients relapsed and 8
patients had radiotherapy, resulting in a negative prog-
nostic value of 94% (95% confidence interval (CI)
9296). Overall, only 12% of patients had additional
radiotherapy compared with 70% after escalated
BEACOPP in the previous HD9 trial[42]. Furthermore,
there was no difference in progression-free or overall sur-
vival compared with earlier trials in advanced Hodgkin
lymphoma. The high negative predictive value of PET
suggests that additional radiotherapy can be omitted in
74% of patients.
Despite the high cure rate, approximately 25% of
patients with Hodgkin lymphoma have relapsed or devel-
oped refractory disease[53]. For relapsed or refractory
Hodgkin lymphoma, the standard treatment is high-
dose chemoradiation followed by autologous stem cell
transplantation. It is common, however, for chemoresis-
tance and radioresistance to coexist in these patients. For
patients with persistent FDG-avid disease after a full
course of chemotherapy, radiotherapy is less beneficial.
These patients are at high risk for relapse and poor prog-
nosis and should be considered for alternative treat-
ments. Therefore, efforts have been made to better
guide patient selection in this regard. Moskowitz
et al.[54] showed by multivariate Cox proportional regres-
sion analysis that treatment response determined by func-
tional imaging is the only independent prognostic factor
for treatment outcome when performed before high-dose
chemoradiation followed by autologous stem cell trans-
plantation. Subsequently, the same group[55] designed a
phase II study, using both pre-salvage chemotherapy
prognostic factors (remission duration51 year, extrano-
dal disease, and B symptoms) and post-salvage chemo-
therapy FDG-PET response in a risk-adapted approach.
This was performed to improve progression-free survival
after high-dose chemoradiation and autologous stem cell
transplantation, as well as to show that a preceding sal-
vage chemotherapy program, documenting that the dis-
ease is still chemosensitive, is mandatory. They started
with 2 cycles of ifosfamide, carboplatin, etoposide (ICE)
in a standard or augmented dose (aICE), followed by
FDG-PET. Patients with a negative PET immediately
proceeded to high-dose chemoradiation followed by auto-
logous stem cell transplantation. In the case of a positive
scan, patients continued with gemcitabine, vinorelbine,
and liposomal doxorubicin. Patients without progressive
disease proceeded to high-dose chemoradiation followed
by autologous stem cell transplantation. One might crit-
icize that it could have been possible that the 2 months
needed for patients to receive this non-cross-resistant che-
motherapy resulted in transplant-ineligibility secondary to
progression of disease or chemotherapy-induced side
effects. The results, however, show that the outcome
for patients with a negative PET after gemcitabine, vinor-
elbine, and liposomal doxorubicin was comparable with
the outcome for patients with a negative PET after ICE-
based therapy. This prospective study provides evidence
that the goal of salvage chemotherapy in patients with
Hodgkin lymphoma should be a negative FDG-PET scan
before high-dose chemoradiation followed by autologous
stem cell transplant.
Non-Hodgkin lymphoma
In both early and advanced stages of aggressive non-
Hodgkin lymphoma, the 1-year progression-free survival
for patients with a positive interim PET ranges from 10 to
50%, compared with 79 to 100% in interim PET-negative
patients[5658]. As summarized in Table 3, several (ongo-
ing) trials are investigating whether patients with a posi-
tive interim PET will benefit from an early switch to a
more intensified approach or even high-dose therapy with
autologous stem cell transplantation. Controlled reduc-
tion of treatment, on the other hand, is only justified in
the favorable young subpopulation, without bulky disease
or International Prognostic Index (IPI) risk factors. Also
for aggressive non-Hodgkin lymphoma, the metabolic
response determined on interim PET is a stronger prog-
nostic factor than the IPI[15].
The results of a phase II risk-adapted trial[59] showed
that early FDG-PET was able to identify those patients
who benefit most from preemptive blood or marrow
transplantation. Patients with a positive PET after 23
cycles of first-line chemotherapy received rituximab, eto-
poside, methylprednisolone, cytarabine and cisplatin (R-
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ESHAP) or rituximab, ifosfamide, carboplatin and etopo-
side (R-ICE), followed by high-dose therapy and autolo-
gous stem cell transplantation; patients with a negative
midtreatment PET completed full-course, standard ritux-
imab, cyclophosphamide, doxorubicin, vincristine and
prednisone (R-CHOP). Of 59 evaluable patients (98%
with large B-cell lymphoma), 33 (56%) had a positive
interim PET, of whom 28 received autologous stem cell
transplantation regardless of stage or IPI. The 2-year
event-free survival of these 28 patients was 75% (95%
CI 6093%). On intention-to-treat analysis, the 2-year
event-free survival was 67% (5386%) in all PET-positive
patients and 89% (77100%) in PET-negative patients.
No association was found between the IPI category and
the interim PET results.
Thus, the predictive value of FDG-PET/CT for
Hodgkin lymphoma is superior overall to the predictive
value for non-Hodgkin lymphoma. The lower negative
predictive value is probably caused by the intrinsically
worse prognosis of non-Hodgkin lymphoma and the
lower positive predictive value is likely to be related to
the higher risk of infections among typically older
patients who are treated with higher dose density and
intensity regimens. Furthermore, the addition of rituxi-
mab induces an inflammatory response by activation of
antibody dependent cellular cytotoxicity and complement
dependent cytotoxicity, resulting in a high rate of false-
positive results[60,61]. Therefore, some trials included a
biopsy[6264] to verify the results of interim PET.
Nevertheless, it must be kept in mind that biopsies are
invasive and can be false-negative due to sampling errors.
Another option is to perform short-term follow-up (clin-
ical, CT and/or PET/CT) to assess for objective evidence
of disease progression.
FDG-PET-guided treatment trials
in solid tumors
Adenocarcinoma of the esophagogastric
junction
Compared with malignant lymphoma, less data are avail-
able in the field of PET-controlled trials in solid tumors
(Table 4). The stage in this field has been set by Lordick
et al.[65] with their frequently cited MUNICON-I trial
(Metabolic response evalUatioN for Individualisation of
neoadjuvant Chemotherapy in esOphageal and esopha-
gogastric adeNocarcinoma), which reports the results of
a PET-guided treatment algorithm in adenocarcinoma of
the esophagogastric junction. Neoadjuvant chemother-
apy is an accepted choice for the treatment of the locally
advanced stage of this tumor type[66,67]. For non-respon-
ders, however, the prognosis is inferior to that of patients
primarily treated with surgery[68,69]. This may be due to
the fact that ineffective neoadjuvant treatment allows
tumor progression during chemotherapy, but also to the
risk of toxic deaths as observed in the MUNICON phase
II trial[65]. This highlighted the necessity to identify those
patients who might potentially benefit from neoadjuvant
chemotherapy. This concept has been realized in the
MUNICON-I trial[65], which prospectively confirmed
that responders to induction chemotherapy can be iden-
tified by metabolic imaging as early as 2 weeks on treat-
ment (Fig. 2). In this trial, a PET scan was performed in
119 patients before the start and after 2 weeks of plati-
num and fluorouracil-based induction chemotherapy.
Patients with a predefined decrease in standardized
uptake value (SUV) of 35% were defined as metabolic
responders, which was based on previous studies by the
Table 4 Main FDG-PET early response-adjusted trials on solid tumors
Reference Study Group PET timing Treatment
[65] Gastroesophageal
cancer,
MUNICON-I
Munich, Heidelberg,
Germany
2 weeks into chemotherapy
(platinum-FU based)
PET responder, complete chemotherapy 12 weeks
þ surgery
PET non-responder, surgery
[72] Gastroesophageal
cancer,
MUNICON-II
Munich, Heidelberg,
Germany
2 weeks into chemotherapy
(platinum-FU based)
PET responder, complete chemotherapy 12 weeks
þ surgery
PET-non-responder, chemoradiationþ surgery
[75] HICON,
NCT01271322
Heidelberg, Germany 2 weeks into EOX PET-responder, complete EOX 3þ surgery
PET-non-responder, DC 1þDC/RTþ surgery
[76] Breast cancer,
CCAM-1101,
NCT01330212
UK NCRI Post TEC 4, post TEC 4,
post TEC 1
Her2þ, CR/PR!docetaxelþtrastuzumab
4þ surgery; PD/SD!NTX 4þ surgeryþRT
ER, CR!TEC 4þ surgery; PR/SD!NAX
4þ surgery
ERþ, responders!TEC 3; non-responders/
ERþ,HER2-!change treatment (depending on
Oncotype)
CR, metabolic complete response; DC, docetaxel, cisplatin; EOX, epirubicin, oxaliplatin, capecitabine; ER, estrogen receptor; FU, fluorouracil;
HER2, human epidermal growth factor receptor 2; HICON, Heidelberg Imaging program in Cancer of the esophago-gastric junction during
Neoadjuvant treatment; MUNICON, Metabolic response evalUatioN for Individualisation of neoadjuvant Chemotherapy in esOphageal and
esophagogastric adeNocarcinoma; NAX, vinorelbine, bevacizumab, capecitabine; NTX, vinorelbine, trastuzumab, capecitabine; PD, metabolic
progressive disease; PR, metabolic partial response; RT, radiotherapy; SD, metabolic stable disease; TEC, docetaxel, epirubicin, cyclophosphamide;
UK NCRI, United Kingdom National Cancer Research Institute.
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same group that assessed and validated the optimum cut-
off level[69,70]. Responders continued to receive neoadju-
vant chemotherapy for 12 weeks and then proceeded to
surgery. Metabolic non-responders discontinued chemo-
therapy and immediately proceeded to surgery. The rate
of major histopathologically confirmed remissions was
58%. Continuation of neoadjuvant chemotherapy in the
responders resulted in a favorable outcome. Median over-
all survival was not reached in metabolic responders com-
pared with a median overall survival of 25.8 months in
metabolic non-responders. Compared with cohorts from
previous studies, one can conclude that the outcome of
metabolic non-responders was not at all compromised by
the early discontinuation of chemotherapy. It must be
emphasized, however, that all data are derived from
single-centre studies and that a randomized multicentre
trial for confirmation would be desirable. The European
Organisation of Research and Treatment of Cancer
(EORTC) is currently planning an international valida-
tion trial of the MUNICON findings, using a central
imaging platform and central quality assurance of PET
and histopathologic response[71].
What we can learn from the approach is that step-by-
step implementation of cut-off values is very important
when metabolic thresholds for response monitoring are
implemented in clinical practice. A higher metabolic
cut-off value of 45% or more would result in higher spe-
cificity for histological response (86% vs 75%)[70], but in
a lower negative predictive value, which would translate
into a bigger proportion of patients from whom chemo-
therapy would be withheld, despite having chemosensi-
tive tumors.
On the basis of the results of the MUNICON-I trial,
the MUNICON-II trial was initiated[72]. In this trial,
Locally Advanced 
AEG
Type I: distal 
esophagus
Type II: cardia
Baseline 18F-FDG-
PET
Continuation 
neoadjuvant 
chemotherapy for 
maximal 12 weeks
Follow-up CT and endoscopy every 3months for 1 
year and every 6months thereafter
119 patients enrolled
- 8 patients non-evaluable / 
excluded
- early death
110 patients evaluable:
- 54 responders*
- 56 non-responders**
2 weeks of 
neoadjuvant 
induction 
chemotherapy
Insufficient uptake
Follow-up 18F-
FDG-PET
Resection
Resection
Non-responder**Responder*
104 patients resected:
- 29/50 responders major 
histopathological 
response
- 0/54 non-responders with 
any histopatholog-
ical response
Figure 2 Study scheme as used by Lordick et al.[65]. AEG, adenocarcinoma of the esophagogastric junction; *responder
(metabolic responder), reduction in SUV 35% compared with baseline FDG-PET/CT; **non-responder (metabolic non-
responder), increase or reduction in SUV535% compared with baseline FDG-PET/CT.
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56 patients with locally advanced adenocarcinomas of
the esophagogastric junction were included. In contrast
to MUNICON-I, where metabolic non-responders pro-
ceeded to surgery, metabolic non-responders in the
MUNICON-II trial were switched to salvage neoadjuvant
chemoradiation before surgical resection in order to
improve histopathologic response, the R0 resection rate
and the prognosis of these patients. The results of this
trial showed an increased histopathologic response after
salvage chemoradiation (26% vs 0% in the MUNICON-I
trial), however, the primary end point of the study to
increase the R0 resection rate from 74% to 94% was
not met. No benefit in prognosis was observed in the
subgroup of PET non-responders. Almost 50% of the
metabolic non-responders showed distant metastases
shortly after chemoradiation, indicating the unfavorable
tumor biology that could not be reversed by radiation
(total dose of 32Gy) plus concurrent chemotherapy (cis-
platin or 5-fluorouracil). The moderate-intensity schedule
was chosen to prevent high toxicity rates, which could
lead to a higher pre-operative drop-out rate and post-oper-
ative morbidity and mortality. Median overall survival of
metabolic non-responders in the MUNICON-II trial was
18.3 versus 25.8 months in MUNICON-I, whereas time
to progression was 15.4 months for MUNICON-II versus
14.1 months for MUNICON-I. When radiotherapy is
part of the regimen, overestimation of FDG uptake due
to the radiation-mediated inflammatory component can
occur, which may persist from weeks to months and
could potentially have confounded metabolic response
assessment. Currently, an international multicentre
PET-guided randomized controlled trial, comparing sal-
vage chemoradiation and other treatment strategies, is on
its way to find out which strategy affects patient out-
come[73,74]. New ongoing trials on the same subject are
the EUROCON trial[74] and the HICON trial[75]. The
EUROCON trial randomizes metabolic non-responders
with localized esophagogastric adenocarcinoma after 2
weeks of chemotherapy to immediate resection or che-
moradiation followed by surgery. The HICON trial[75] is
a prospective, non-randomized, explorative imaging study
to evaluate the value of PET as a predictor of histopatho-
logic response to salvage neoadjuvant chemoradiation
in metabolic non-responders. Metabolic non-responders
2 weeks after the start of neoadjuvant chemotherapy
(EOX (epirubicin, oxaliplatin, capecitabine) or EOF
(epirubicin, oxaliplatin, 5-fluorouracil)) are taken to
intensified taxane-based chemoradiation (docetaxel/
cisplatinþ 45Gy) before surgery. FDG-PET scans are
performed before and after 14 days of standard neoadju-
vant therapy as well as after the first cycle of salvage
docetaxel/cisplatin chemotherapy and at the end of che-
moradiation (Table 4).
Other solid tumors
In solid tumors other than adenocarcinoma of the eso-
phagogastric junction, a first step has been taken in
breast cancer. The ongoing CCAM-11-01 phase II
trial[76] is investigating the feasibility of FDG-PET-
guided chemotherapy and hormone therapy in patients
with newly diagnosed invasive breast cancer (Table 4). In
this trial, patients are divided according to receptor status
into three groups. Group 1 consists of HER2þ patients
(positive for the human epidermal growth factor receptor
2), which includes ERþ (estrogen receptor positive),
ER, and PRþ (progesterone receptor negative).
Group 2 consists of ER patients (including triple nega-
tive and ER/PR/Her2 patients) and group 3 of ERþ
patients (including ERþ/PRþ/Her2 and ERþ/PR/
Her2 patients). All groups receive docetaxel, epirubicin
and cyclophosphamide (TEC regimen). For ERþ/Her2
patients, subsequent therapy after TEC course 1 depends
on the Oncotype score. For other patients, treatment with
TEC is repeated every 21 days for up to 4 courses in the
absence of disease progression or unacceptable toxicity.
Patients in group 1 are being evaluated after 4 courses of
TEC. Patients who achieve complete or partial remission
receive 4 courses of docetaxel and trastuzumab followed
by surgery. Patients with progressive or stable disease
receive vinorelbine, trastuzumab and oral capecitabine
(NTX regimen) for 4 courses followed by surgery. After
surgery, patients receive radiotherapy (when indicated)
and maintenance trastuzumab for 1 year. ER-positive or
PR-positive patients also receive hormonal therapy for 5
years. The second group of patients (ER) are also eval-
uated after 4 courses of TEC. Patients who achieve com-
plete remission receive 4 more courses of TEC and
undergo surgery. Patients who achieve partial remission
or stable disease receive 4 courses of vinorelbine, bevaci-
zumab and capecitabine (NAX regimen) followed by sur-
gery. Group 3, ERþ patients undergo a PET scan 2
weeks after finishing 1 course of TEC. Patients receive
3 additional courses of TEC if the SUV decreases45%.
Patients with an SUV decrease 5% (after 1 course of
TEC therapy) receive additional therapy depending on
the Oncotype results. The primary outcome measure of
this trial is the pathological response rate.
Take home messages
A large number of studies have shown that FDG-PET is a
robust, reliable, easy-to-adopt tool for early response mon-
itoring in several malignancies. Based on these studies,
several (ongoing) clinical trials are investigating the
impact of FDG-PET-based treatment changes on patient
outcome. The first PET-driven clinical trials on malignant
lymphoma and solid tumors, published by Dann et al.[29]
and Lordick et al.[65] (the MUNICON trials) prospec-
tively showed the feasibility of a PET-guided treatment
algorithm in a multidisciplinary setting leading to an over-
all better treatment outcome. The results of these trials
are an important step forward in tailoring (multimodal)
treatment in accordance with tumor biology. The trials
provide a model for designing response-guided treatment
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algorithms in other malignancies, such as lung, head and
neck and ovarian cancer, for which induction treatment
has a potential role and the algorithms need to be
addressed in randomized phase III trials. The application
of FDG-PET for response-adjusted treatment in clinical
trials is still in its infancy. Much more work has to be
done to provide definite proof of the clinical impact of
metabolic response monitoring, to establish FDG-PET as
an imaging biomarker to adjust and personalize cancer
therapy. The preliminary findings discussed in this review
call for systematic implementation of FDG-PET in ran-
domized trials comparing PET-controlled strategies in
order to be able to adequately position FDG-PET in treat-
ment time lines and bring about a paradigm shift in the
evidence-based approach of individualized patient man-
agement of malignancies.
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